As­traZeneca's can­cer com­bo wins sec­ond nod in one month, this time in lung can­cer

Weeks af­ter cel­e­brat­ing the first can­cer win for its Imfinzi and Imju­do duo, As­traZeneca is once again break­ing out the par­ty hats.

The mon­o­clon­al an­ti­body com­bo scored a la­bel ex­pan­sion on Thurs­day in metasta­t­ic non-small cell lung can­cer (NSCLC) along­side plat­inum-based chemother­a­py. Just last month, the drugs won a nod in un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma (HCC), the most com­mon type of liv­er can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.